$AZRX News - AzurRx CEO Provides Shareholders With a "State of the Union" Communication

Follow Us on Facebook   Follow Us on Twitter   Follow Us on You Tube   Follow Us on Linked In   Subscribe To Our Feed

Financial News Media Featured News

Published - December 1, 2016

$AZRX News - AzurRx CEO Provides Shareholders With a "State of the Union" Communication - (FinancialNewsMedia.com Wire)

BROOKLYN, N.Y., - (http://www.financialnewsmedia.com News Alert) - AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, announced today the release of a Company overview as presented by AzurRx's President & CEO, Thijs Spoor.

Mr. Spoor began the communication by stating, "This Company overview serves to provide shareholders with a perspective on AzurRx, its evolution and future potential. Let me begin with the fundamentals. We have a clear, focused plan for value creation, building our pipeline assets with a short-term, lower-risk development pathway, an experienced management team and first-class advisors.

We believe that our focus on non-systemic therapies represents a new frontier for developing therapies. Our pipeline, led by MS1819 and followed by AZX1101, is moving ahead and we have further strengthened and we continue to expand our global patent portfolio. Non-absorbable drugs are a unique subset of orally administered agents that exert their therapeutic effects locally in the GI tract. In contrast to traditional drugs, which are designed to be rapidly absorbed, achieve therapeutic plasma levels, and then be eliminated by multiple pathways, non-absorbable drugs are designed to only act locally in the gut. It is our belief that if drugs are not absorbed into the bloodstream, then it is very difficult for them to reach the liver, heart, brain or other organs, and thus we believe that the chance of having serious side effects is decreased. Read this and more news for AZRX at http://financialnewsmedia.com/profiles/azrx.html

MS1819 - We continue to make progress with our lead agent MS1819-SD, a yeast derived recombinant lipase, for the treatment of exocrine pancreatic insufficiency (“EPI”) related to chronic pancreatitis (“CP”) and cystic fibrosis. We previously announced the initiation of the Phase II trial of MS1819 in EPI due to CP. We anticipate active participation from the sites in Australia and New Zealand in this un-blinded dose escalation trial, with initial results anticipated in the first half of 2017. With a potentially superior efficacy profile, we expect MS1819 to provide a true clinical benefit to EPI patients, offering materially improved efficacy and a dramatically reduced pill burden. Commercially, the EPI market, consisting of porcine derived products, was estimated to be approximately $1.5 billion in 2015 and is projected to increase to approximately $2.85 billion by 2023, according to market research firm Transparency Market Research.

AZX1101 - Our second development stage agent, AZX1101, is a complex biologic in development for the prevention of nosocomial (hospital acquired) bacterial infections. Discovered in-house at AzurRx’s labs, AZX1101 acts by blocking the activity of a broad range of antibiotics from acting within the GI tract, thereby preventing toxicity of intravenous antibiotics to gut bacteria, and thus maintaining a healthier gut flora balance. We expect to file an Investigational New Drug Application for AZX1101 in 2017. While the potential applications of AZX1101 are broad, we intend to develop this agent for the prevention of clostridium difficile (C. diff) infection. The Centers for Disease Control has estimated that roughly 1.7 million hospital associated infections (i.e. ~5% of the number of hospitalized patients) cause or contribute to 99,000 deaths each year in the U.S., with the annual cost ranging from $4.5 billion to $11 billion.

Expanding Management - We have a terrific team of experienced, dedicated professionals at both our French and U.S. locations and intend to continue to strengthen our management and advisory boards with clinical experts in the fields of gastroenterology, cystic fibrosis, and infectious disease.

Value Creation - In summary, with MS1819 and AZX1101, we have a clear, focused plan for value creation, with significant milestones over the next 6-12 months. We also plan to bolster the team’s capabilities as the Company expands into the rapidly evolving infectious disease and microbiome space. Thijs Spoor, CEO of AzurRx, noted; “It is clear that novel therapies are urgently needed for gastro-intestinal and infectious diseases and we are focused on driving forward the development of our pipeline to provide patients around the world with new products that provide true clinical benefit. This is an exciting time for AzurRx as we build towards near-term value inflections.”

About AzurRx BioPharma - AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the Company can be found at www.azurrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigations Reform Act of 1995. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the development and testing of our drug candidates, the regulatory approval process, our ability to secure additional financing, the protection of our patent and intellectual property, the success of strategic agreements and relationships, and the potential commercialization of any product we may successfully develop. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

For more information:
AzurRx BioPharma, Inc.
760 Parkside Avenue,
Suite 217
Brooklyn, NY 11226

Source: AzurRx BioPharma, Inc.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand seven hundred dollars for AzurRx BioPharma, Inc. news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF AzurRx BioPharma, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
© 2016 FinancialNewsMedia.com. All Rights Reserved. Created, Designed, Owned & Operated by FN Media Group, LLC.
Follow Us on Facebook   Follow Us on Twitter   Follow Us on You Tube   Follow Us on Linked In   Subscribe To Our Feed
FinancialNewsMedia.com (FNM) is a third party publisher and news disemmination solutions provider of multimedia platforms that enable officers & directors, corporate communicators, public relations and investor relations officers to leverage content to engage with all their key audiences. Any ideas and opinions presented in any FNM News Alerts, Video clips, Press Releases, RSS Feeds or Social Network Posts are for informational purposes only, and do not reflect the opinions of FNM or any of its affiliates, subsidiaries or partners. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT CONTAINED HEREIN BE INTERPRETED TO REPRESENT TRADING OR INVESTMENT ADVICE. All viewers agree that under no circumstances will FNM, its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information contained on this or any affiliated website. Read Full Disclaimer.